Dermata Therapeutics Stock Shares Outstanding

DRMA Stock  USD 1.14  0.01  0.87%   
Dermata Therapeutics fundamentals help investors to digest information that contributes to Dermata Therapeutics' financial success or failures. It also enables traders to predict the movement of Dermata Stock. The fundamental analysis module provides a way to measure Dermata Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dermata Therapeutics stock.
As of November 25, 2024, Common Stock Shares Outstanding is expected to decline to about 185.2 K.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Dermata Therapeutics Company Shares Outstanding Analysis

Dermata Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Shares Outstanding

 = 

Public Shares

-

Repurchased

More About Shares Outstanding | All Equity Analysis

Current Dermata Therapeutics Shares Outstanding

    
  2.04 M  
Most of Dermata Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dermata Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Dermata Shares Outstanding Driver Correlations

Understanding the fundamental principles of building solid financial models for Dermata Therapeutics is extremely important. It helps to project a fair market value of Dermata Stock properly, considering its historical fundamentals such as Shares Outstanding. Since Dermata Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dermata Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dermata Therapeutics' interrelated accounts and indicators.
0.950.95-0.41-0.98-0.740.76-0.41-0.741.00.721.00.990.72-0.93-0.41-0.15-0.47
0.951.0-0.59-0.96-0.90.79-0.59-0.770.960.780.950.930.78-1.0-0.59-0.15-0.63
0.951.0-0.6-0.96-0.90.8-0.6-0.770.960.780.950.930.78-1.0-0.6-0.16-0.63
-0.41-0.59-0.60.50.82-0.551.00.33-0.4-0.37-0.41-0.36-0.370.611.00.580.94
-0.98-0.96-0.960.50.77-0.810.50.82-0.97-0.63-0.98-0.99-0.630.930.50.180.54
-0.74-0.9-0.90.820.77-0.770.820.61-0.75-0.76-0.74-0.7-0.760.920.820.330.85
0.760.790.8-0.55-0.81-0.77-0.55-0.750.730.520.760.790.52-0.78-0.55-0.5-0.74
-0.41-0.59-0.61.00.50.82-0.550.33-0.4-0.37-0.41-0.36-0.370.611.00.580.94
-0.74-0.77-0.770.330.820.61-0.750.33-0.72-0.28-0.74-0.83-0.280.740.33-0.120.35
1.00.960.96-0.4-0.97-0.750.73-0.4-0.720.761.00.980.76-0.94-0.4-0.11-0.45
0.720.780.78-0.37-0.63-0.760.52-0.37-0.280.760.720.631.0-0.81-0.37-0.14-0.48
1.00.950.95-0.41-0.98-0.740.76-0.41-0.741.00.720.990.72-0.93-0.41-0.15-0.47
0.990.930.93-0.36-0.99-0.70.79-0.36-0.830.980.630.990.63-0.9-0.36-0.1-0.42
0.720.780.78-0.37-0.63-0.760.52-0.37-0.280.761.00.720.63-0.81-0.37-0.14-0.48
-0.93-1.0-1.00.610.930.92-0.780.610.74-0.94-0.81-0.93-0.9-0.810.610.150.65
-0.41-0.59-0.61.00.50.82-0.551.00.33-0.4-0.37-0.41-0.36-0.370.610.580.94
-0.15-0.15-0.160.580.180.33-0.50.58-0.12-0.11-0.14-0.15-0.1-0.140.150.580.72
-0.47-0.63-0.630.940.540.85-0.740.940.35-0.45-0.48-0.47-0.42-0.480.650.940.72
Click cells to compare fundamentals

Dermata Shares Outstanding Historical Pattern

Today, most investors in Dermata Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Dermata Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Dermata Therapeutics shares outstanding as a starting point in their analysis.
   Dermata Therapeutics Shares Outstanding   
       Timeline  
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition

Dermata Common Stock Shares Outstanding

Common Stock Shares Outstanding

185,212

At present, Dermata Therapeutics' Common Stock Shares Outstanding is projected to decrease significantly based on the last few years of reporting.
Based on the latest financial disclosure, Dermata Therapeutics has 2.04 M of shares currently outstending. This is 98.87% lower than that of the Biotechnology sector and 98.09% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 99.64% higher than that of the company.

Dermata Shares Outstanding Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dermata Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dermata Therapeutics could also be used in its relative valuation, which is a method of valuing Dermata Therapeutics by comparing valuation metrics of similar companies.
Dermata Therapeutics is currently under evaluation in shares outstanding category among its peers.

Dermata Fundamentals

About Dermata Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Dermata Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Dermata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dermata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dermata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dermata Therapeutics Stock:
Check out Dermata Therapeutics Piotroski F Score and Dermata Therapeutics Altman Z Score analysis.
For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(13.36)
Return On Assets
(0.91)
Return On Equity
(1.73)
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.